CV Jamal Mahajna

Home , Kiryat Shmona

CV Jamal Mahajna

Date: December 2020

A. Personal Details

Full name: Jamal Mahajna

Date of birth (month/year): June 1957

Country of birth: Israel

Date of immigration to Israel. N/A

Citizenship: Israeli

ID (or passport) number: 054799531

Family status; M+2

Full home address: Street, house number, town, postal code: 9/4 Dalia street, Nof HaGalil 1709118.

Home: phone, fax, cell phone numbers: Home phone: 04-6012277; Mobile: 050- 4242634

E-mail address: [email protected]; [email protected]

B. Higher Education:

1977-1980 Hebrew University in Jerusalem: B.Sc. Biology. 1980-1982 Hebrew University in Jerusalem: M. Sc. Dept. Molecular Genetics, Amos Oppenheim's Laboratory. Regulation of Lambda Gene Expression 1982-1986 Hebrew University in Jerusalem: Ph.D. Dept. Molecular Genetics, Amos Oppenheim's Laboratory. Regulation of Lambda Gene Expression Additional Education, Training and Professional Certificates 1986-1987 Postdoc 1: Biolume Ltd., Haifa, Israel. Genetic analysis of the bioluminescence system of Vibrio fischeri. 1987-1991 PostDoc 2: Oncogene Science Inc. Uniondale, New York, USA: Development of cell-based transcription screens 1997- 1998 Sabbatical leave at the Biology Department, Technion- Israeli Institute of Technology, Haifa, Israel. Hosted by Prof. Gera Nufeild, Technion, Haifa , Israel.

C. Academic Appointments and Academic Administrative Positions in Institutions of Higher Education:

Appointments at academic institutions 1998-2000 Research Investigator at the Regional R&D Center-The Galilee Society, Shefa-Amr, Israel.

2001-2002 Scientific Director of the R&D Regional Center-The Galilee Society, Shefa-Amr, Israel.

2002-present Research Investigator and Department Head of Cancer Drug Discovery program, MIGAL, Kiryat Shmona, Israel.

2005-2009 Lecturer at Tel-Hai College, the Department of Biotechnology, Kiryat Shmona, Israel.

2010-2016 Senior Lecturer at Tel-Hai College, the Department of Biotechnology, Kiryat Shmona, Israel.

2011-2016 Head of the Nutritional Sciences Department, Tel Hai College, Kiryat Shmona, Israel.

2016-present Associate Professor at Tel-Hai College, the Department of Biotechnology and Nutritional Sciences, Kiryat Shmona, Israel.

October 2018 Visiting Professor at the department of Dietetics of Life Sciences University (SGGW), Warsaw, Poland

Positions in Non-academic & Research Institutions 1991-1995 Oncogene Science Inc. Uniondale, New York, USA. Senior Research Scientist. Cancer Department, group leader of retinoid and angiogenesis drug discovery programs.

1995-1997 Oncogene Science Inc. Uniondale, New York, USA. Research Investigator. Cancer Department, group leader of apoptosis and tyrosine kinases drug discovery programs.

2001-2003 Chief Scientific Officer of PlasaMed, Misgav Technological Incubator. Israel

2005-2008 Founder and Chief Scientific Officer of MyCure, Meytav Technological Incubator, P.O.B 408, Kiryat Shmona 11013, Israel

D. Teaching :

Teaching at Academic Institutions 1. Biotechnology in Medical Sciences. Biotechnology Department, Tel-Hai College, Kiryat Shmona, Israel. 2. Laboratory in medical Sciences. Biotechnology Department, Tel-Hai College, Kiryat Shmona, Israel. 3. Nutrition and Cancer. Nutritional Sciences Department, Tel-Hai College, Kiryat Shmona, Israel. 4. Molecular Bases of cancer. MSC students, Biotechnology Department, Tel- Hai College, Kiryat Shmona, Israel. 5. Nutrition for Cancer Prevention. Nutritional Sciences Department, Tel-Hai College, Kiryat Shmona, Israel. 6. Molecular Nutrition. Nutritional Sciences Department, Tel-Hai College, Kiryat Shmona, Israel

E. Supervision of Graduate Students:

1. Abdul Rahim Aisheh, MSC, Palestinian Medicinal Plants as Therapeutics for CML, An-Najah University, Nablus, Palestine, 1999-2001. 2. Majed Yassin, PhD, Medicinal Mushrooms As potential therapeutics for CML, Haifa University, Israel, Co-supervision with Prof. Solomon Wasser, 2002-2006. 3. Benzi Zaidman, PhD, Androgen receptor-dependent and independent mechanisms underline the anti-prostate cancer activity of Ganoderma Lucidum, Haifa University, Israel, Co-supervision with Prof. Solomon Wasser, 2003-2007. 4. Rumiana Petrovabg, PhD, Medicinal Mushroom Modulators of NF-KB activity as Potential Therapeutics for Breast Cancer, , Haifa University, Israel, Co- supervision with Prof. Solomon Wasser, 2004-2008. 5. Hila Tuvi, MSC, Medicinal Mushrooms As Inhibitors of Bcr-Abl activity as potential therapy for CML, Haifa University, Israel, Co-supervision with Prof. Solomon Wasser, 2005-2007. 6. Nili Ruimi, MSC, Mushroom Substances regulate the expression of iNOS in RAW264.7 macrophage cells, Haifa University, Israel, Co-supervision with Prof. Solomon Wasser, 2006-2008.

7. Einat Gochman, PhD, Modulation of tyrosine kinases activity by NF-kB induced iNOS expression, Technion-Rambam Medical School, Israel, Co-supervision with Prof. Abraham Reznick, 2007-2010. 8. Yaniv Menahim, MSC, Mushrooms that regulating NF-KB pathway in Imatinib- resistant CML, Haifa University, Israel, Co-supervision with Prof. Solomon Wasser, 2008-2010. 9. Michal Werner, MSC, Differentiation therapy to B cell lymphoma, Tel Aviv University, Israel, Co-supervision with Prof. Shai Izraeli, 2008-2010. 10. Nesli Dotan, PhD, Mushroom substances from coprinus comatus as potential therapeutics for hormone-refractory prostate cancer, Haifa University, Israel, Co-supervision with Prof. Solomon Wasser, 2007-2011 11. Mamduh Katib, MSC, MBP competitors as modulators of Abl activity, Tel Hai College, Israel, 2009-2011. 12. Ola Orgil, MSC, The levels of punicalgains, gallagic, ellagic and gallic acids in Pomegranate organs and their relation to antioxidant activity and inhibition of two cancer cells lines, Tel Hai College, Israel, Co-supervision with Prof Rachel Amir, 2010-2012. 13. Einav Ratzon, MSC, Anti-tumor activity of novel platinum (IV) complexes, Anti- tumor activity of novel platinum (IV) complexes, Tel Hai College, Israel, 2010- 2012. 14. Amir Bahat, MSC, Allosteric inhibitors for Bcr-Abl as therapeutics for CML, Tel Hai College, Israel, 2011-2013. 15. Shay Gefen Roitman, MSC, Allosteric inhibitors for Bcr-Abl as therapeutics for CML, Tel Hai College, Israel, 2012-2014. 16. Farah Reslan, MSC, Involvement of EMT process in prostate Cancer, Tel Hai College, Israel, 2013-2015. 17. Ofer Regev, MSC, Drug resistance and collateral sensitivity mediated in EMT regulators in Ph-positive leukemia, Tel Hai College, Israel, 2014-2016. 18. Meshel Nickola, MSC, Elucidation the mechanism of action of Crizotinib as an Abl allosteric inhibitor, Tel Hai College, Israel, 2014-2016. 19. Noa Kidan, MSC, Involvement of catenin in bone marrow homing and disease progression of Ph positive leukemia, Tel Hai College, Israel, 2014-2016. 20. Lena Avinery ,MSC, Tel Hai College, Israel, 2015-present. 21. Tamir lev , MSC, Tel Hai College, Israel, 2015-present.

22. Nimas Naser, MSC, Tel Hai College, Israel, 2016-present. 23. Rina Adawi, MSC, Tel Hai College, Israel, 2016-present. 24. Hatem Mahmud, MSC, Tel Hai College, Israel 2017-present 25. Yoni Dalali, MD, Joint supervision with Dr. Inbal Dahan, Bar-Ilan Medical School, Israel 2018-2019. 26. Yifat Carmi, PhD student, Ben-Gurion University, Israel, co-supervision with Prof. Jacob Gopas 2018-present. 27. Orr Shahar, MSC, Tel-Hai College, Israel 2019-present 28. Sabrin Nafahh, MSC, Tel hai College, Israel 2020-present 29. Katty Hana, , MSC, Tel hai College, Israel 2021-present

F. Research Grants

1. The Middle East Cancer Consortium (MECC) , Medicinal plants as a source of therapeutics for the treatment of hormone-refractory prostate cancer, collaboration with Prof. M.S. Shtayeh, An-Najah University, amount of 30,000$, 1999-2000, Publication #9. 2. Israel Ministry of Science, Natural Products As inhibitors of VEGFR, amount of 60,000$, 1999-2001. 3. Israel Ministry of Science, Medicinal Mushrooms As modulators of BCR/ABL, amount of 60,000$, 2000-2002 4. The Middle East Cancer Consortium (MECC), Synthesis and activity of novel tyrosine kinase inhibitors, amount of 30,000$, 2000-2002. 5. ICRF, Natural Products to overcome Imatinib-refractory CML, amount of 30,000$, 2002-2004. 6. Israel Ministry of Science, Botanical steroids as potential prostate cancer therapeutics, , amount of 60,000$, 2004-2006. 7. Israel Ministry of Science, Mushroom Substances As anticancer Agents, amount of 60,000$, 2005-2007. 8. Israel Ministry of Science, Natural products as modulators of NFKB activity to improve HSVtk-based cancer gene therapy Mushroom Substances As anticancer Agents, amount of 60,000$, 2005-2008 9. Israeli-Palestinian Science Foundation (IPSO), Targeting the Myristoyl Binding Pocket (MBP) in Bcr-Abl: A Rational Approach for the Design of Therapeutics

Against Philadelphia Chromosome, collaboration with Dr. Yousef Najajreh, Al-Quds University, Prof. Amiram Goldblum, Hebrew University, amount of 30,000$, 2006-2008. Publication #33. 10. Israel Ministry of Science, Overcoming acquired resistance in molecular therapy: inhibition of alternative pathways in Gleevec-refractory CML, amount of 60,000$, 2007-2010. Publication #26, #33. 11. DFG (Trilateral Palestinian-Israel-German Project), Targeting the Myristoyl Binding Pocket (MBP) in Bcr-Abl: A Rational Approach for the Design of Therapeutics Against Philadelphia Chromosome, collaboration with Dr. Yousef Najajreh, Al-Quds University, Prof. Amiram Goldblum, Hebrew University, Prof. Martin Ruthardt, Goethe University, amount of 125,000 Euro, 2007-2013, Publications #31, #35, #37, #38, #39. 12. Israel Cancer Association, Risk assessment of herb-chemotherapy interactions in women with gynecological cancer using herbs during chemotherapy: an integrated clinical and basic science study, collaboration with Prof. Eran Ben- Arye, Technion, amount 45,000 NIS, 2014-2015. 13. Agency for Galilee Bio-Medical Research, Evaluation of Nephrotoxicity of Novel Platinum (IV)-Fatty Acid Conjugates in in vitro and in animal model. Amount 120,000 NIS 2015-2016. 14. Israel Ministry of economics, Kamin program, Development of allosteric inhibitors targeting novel regulatory elements for cancer therapy. Amount 800,000 NIS 2-15-2018. 15. Israeli Ministry of Health, Tumor microenvironment mediated drug resistance in ovarian cancer. 250,000 NIS 2020-2022. 16. Israeli Ministry of Negev and Galilee, The role of ROR kinase family in hematological malignances. 120,000 NIS 2021-2023

G. Active Participation in Conferences

Oral Presentation in Scientific Conferences (2005-present)

1. October 2005- the 3rd Third International Medicinal Mushroom Conference "Medicinal Mushroom Substances As Molecular Therapy For Prostate Cancer" Port Townsend, WA USA. 2. March 2007-Frontiers of Science and Engineering 2007 Medicinal Mushroom Substances As Molecular Therapy For Prostate Cancer" Seville, Spain

3. September 2007-The 4th International Medicinal Mushroom Conference "Medicinal Mushroom Substances As Molecular Therapy For Prostate Cancer", Ljubljana, Slovenia 4. November 2007-The World Science Forum "Targeting the Myristoyl Binding Pocket (MBP) in Bcr-Abl: A Rational Approach for Designing Therapeutics for CML" Budapest, Hungary 5. October 2008-13th World Congress on Advances in Oncology and 11th International Symposium on Molecular Medicine "Overcoming acquired resistance in Gleevec-refractory CML" Crete, Greece. 6. May 2009- Scientists and Scholars: Advancing Human Right "A regional collaboration Project for the Development of Novel CML therapy", Rabat, Morocco. 7. September 2009- The 5th International Medicinal Mushroom Conference " Modulation of iNOS Expression by Medicinal Mushrooms: Anti- inflammatory and Anti-cancer Potentials", Nantong, China. 8. October 10, 2010. Galilee Biomedical conference. Synthesis, Characterization and In Vitro Efficacy of novel Cisplatin (IV) Pro-drugs that Overcome Intrinsic Resistance of Cisplatin 9. Sep 25, 2011, The 6th International Medicinal Mushroom Conference, Zagreb, Croatia "Biologically Active Substances from Culinary-Medicinal Mushroom Coprinus comatus as Modulators of Androgen Receptor Activity in Prostate Cancer Cell Lines" 10. Sep 25, 2011, The 6th International Medicinal Mushroom Conference, Zagreb, Croatia " Oleic acid is the active component in the mushroom Daedalea gibbosa that inhibits Bcr-Abl kinase auto-phosphorylation activity" 11. Oct 6-8, 2011, 16th World Congress on Advances in Oncology and 14th International Symposium on Molecular Medicine "Allosteric Inhibitors of Abl kinase as CML therapeutics". Rhodes Island, Greece 12. Oct 25, 2011 2nd Galilee Biomedical Conference, Kiryat Shmona "Allosteric Inhibitors of Abl kinase as CML therapeutics". 13. Sep 13, 2012; The annual meeting of Clinical Nutrition: Nutrition for Cancer starvation. 14. April 19, 2013; Snail overexpression in Ph-positive cells confers drug resistance to AKIs. Laboratory for Tumor Stem Cell Biology, Department of Hematology, J.W. Goethe University, Frankfurt, Germany. 15. May 27, 2013. Mushrooms Substances as Prostate Cancer Therapeutics. Israel Nutrition Week, preventive nutrition, Tel-Aviv. 16. Sep 27, 2103. Snail overexpression confers resistance to Abl kinase inhibitors and collateral sensitivity to Gemcitabine in Ph-positive leukemic cancer cells. ECCO 17 - 38th ESMO- 32nd ESTRO European Cancer Congress, Amsterdam. 17. August 31 2015, MEDINICAL MUSHROOMS TO OVERCOME AQUIRED RESISTANE IN PH POSITIVE LEUKEMIA. The first International Conference on Natural Product for Cancer Prevention and Therapy. Istanbul, Turkey. 18. Oct 8, 2015, Potential use of allosteric inhibitors as strategy to overcome drug resistance in Ph-positive leukemia. 20th World Congress on Advances in Oncology and 18th International Symposium on Molecular Medicine, Athens, Greece

19. May 29, 2019, EVALUATION ABILITY OF NATURAL PRODUCTS IN OVERCOMING TUMOR MICRONVIROMENT (TME)- MEDIATED CHEMORESISTANCE IN OVARIAN CANCER. 4th International Conference on Natural Products Utilization From Plants to Pharmacy Shelf ICNPU-2019, Albena, Bulgaria.

Posters presented in scientific conferences (2005-present)

1. Zaidman BZ, Mahajna J, Wasser SP. Poster presented at the 4th Congress of the Federation of the Israel Societies for Experimental Biology, February 2005, Eilat, Israel. "Secondary metabolites from edible and medicinal mushrooms as molecular therapy for prostate cancer". 2. Mahajna J., Zaidman BZ, Wasser SP. Poster presented at the 3rd International Medicinal Mushroom Conference, October 2005, Port Townsend, Washington, USA. "Secondary metabolites from edible and medicinal mushrooms as molecular therapy for prostate cancer". 3. Roumyana D. Petrova, Nili Ruimi, Sherbel Sussan, Solomon P. Wasser, Eviatar Nevo, Abraham Z. Reznick, and Jamal Mahajna. Poster presented in the 4th International medicinal mushroom conference, Sep 2007, Ljubljana, Slovenia. "Inhibitory Effects of Marasmius oreades Extract Fractions on NF- kB Activation Pathway". 4. Nili Ruimi, Solomon Wasser and Jamal Mahajna. Poster presented in ISOFRR 2007. The 23th annual meeting of the Israeli Society for Oxygen and Free Radical Research, Dec 2008, Tel Aviv University, Israel. 5. Roumyana D. Petrova, Nili Ruimi, Sherbel Sussan, Solomon P. Wasser, Eviatar Nevo, Abraham Z. Reznick, and Jamal Mahajna. Poster presented in FISEB 2008, Eilat, Israel. "Inhibitory Effects of Marasmius oreades Fractions on NF-kB Activation Pathway". 6. Nili Ruimi, Haithem Rwashdeh , Solomon Wasser and Jamal Mahajna Poster presented in ISOFRR 2008. The 24th annual meeting of the Israeli Society for Oxygen and Free Radical Research, Dec 2008, Wingate Institute, Israel. " Modulation of iNOS expression by medicinal mushrooms: anti- inflammatory and anti-cancer potentials". 7. Gochman E, Mahajna J, Reznick A.Z. Poster presented in the Federation of European Biochemical Societies (FEBS) "Mechanisms, Consequences and Detection of Free Radical-Mediated Oxidative Protein Modification". April 2009, Antalya, Turkey. "The involvement of Reactive Nitrogen Species (RNS) in modulating transcription factor NF-κB and MAP kinases (MAPKs) pathways in colon cancer cells". 8. Riad Agbaria, A Konson , JA Mahajna , G Rimon. Poster presented in The 6th Annual Conference of the ISGCT. May 4, 2009. Ben Gurion University, Beer-Sheva, Israel. "effect of Herpes simplex virus thymidine kinase gene transduction on tumor cell biology 9. Dotan, N, Wasser, S and Mahajna, J " The 5th International Medicinal Mushroom Conference-Sep 2009, Nantong, China "Crude Extracts from the Culinary-medicinal Mushroom Coprinus comatus influence Androgen Receptor activity in Prostate Cancer cell line Mushroom". 10. Einat Gochman, Jamal Mahajna and Abraham Reznick in the 25th annual meeting of the Israeli Society for Oxygen and free Radical research" Dec 13, 2009. A dual mechanism of NF-kB activation by peroxynitrite through p38

MAP kinase dependent IKBa-phosphorylation, versus IKBa nitration in colon cancer cells. 11. Afsar Mian, Anna Metodieva, Yousef Najajreh, Hubert Serve1, Oliver Ottmann, Jamal Mahajna and Martin Ruthardt , in the 52nd ASH Annual Meeting and Exposition, December 4-7, 2010. The Degree of Response of Philadelphia Chromosome Positive Acute Lymphatic Leukemia to Allosteric Inhibition by GNF-2 Depends on the Presence of Either p185-BCR/ABL or p210-BCR/ABL 12. Hazem Khamaisi ,Mamduh Khatteb ,Linda Braik ,Nida Eghreib ,Amiram Goldblum ,Martin Ruthardt ,Yousef Najajreh ,Jamal Mahajna , in the 6th FISEB, Feb 7-10,2011.Myristate analogs as BCR/ABL allosteric inhibitors for the treatment of Philadelphia positive leukemia 13. Einav Ratzon , Yousef Najajreh , Rami Salem , Nili Ruimi , Linda Braik , Hazem Khamaisi , Martin Ruthardt , Jamal Mahajna, in the 6th FISEB, Feb 7- 10, 2011. Synthesis, characterization and in vitro efficacy of novel Cisplatin- IV pro drugs overcoming intrinsic resistance to Cisplatin 14. Nili Ruimi, Mamduh Khatteb ,Yousef Najajreh ,Martin Ruthardt ,Jamal Mahajna, the 6th FISEB, Feb 7-10, 2011. Cooperation between GNF-2 and Abl kinase inhibitors (AKIs) in overcoming BCR/ABL T315I mutation 15. Nesly Dotan , Hazem Khamaisi ,Solomon P. Wasser ,Jamal Mahajna, in the 6th FISEB, Feb 7-10, 2011. Biologically active substances from culinary- medicinal mushroom Coprinus Comatus as modulators of androgen receptor activity in prostate cancer cell lines 16. Sani Kast, N., J. Mahajna, Y. Najajreh, M. Ruthardt and A. Goldblum (2011). In the 9th International Conference on Chemical Structures, June 5-9 2011, Noordwijkerhout. The Netherlands. New Types Of Alloseric Inhibitors Against Bcr-Abl, Using Multiple Pharmacophore Models 17. Mamduh Khateb, Yousef Najajreh, Martin Ruthardt and Jamal Mahajna (2012). In Molecular Targeted Therapies: Mechanisms of Resistance, May 9- 12 San Diego, Ca, USA. Overcoming acquired resistance in Ph + leukemia. 18. Mahajna, J., Khamaisie, H., Ruimi, N., Agbarya, A., Eshel, E., Dally, N., Mian, AA, and Ruthardt, M. (2014). 794: Crizotinib is an allosteric ABL- inhibitor targeting both native BCR/ABL and BCR/ABL-T315I in vitro and in vivo models of PH+ leukemia. July 5-8, Munich, Germany. EACR meeting. 19. O Regev, N Kidan, H Khamisie, J Mahajna (2016). Crizotinib overcomes microenvironment mediated drug resistance in Ph positive leukemia. July 8- 12, Manchester, UK (European Journal of Cancer, S92-S93). 20. Jamal Mahajna, Noa Kidan, Hazem Khamaisie and Martin Ruthardt (2017). Ectopic expression of Snail and Twist in Ph+ leukemia cells upregulates CD44 expression and alters their differentiation potential. 19th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy Estoril Congress Centre, Estoril, Portugal – October 12-15, 2017. 21. Jamal Mahajna, Hazem Khamaisi, Hatem Mahmoud , Yifat Carmi Koren and Jacob Gopas (2020). Mesenchymal stem cells (MSC) Confer chemoresistance to Ovarian Cancer. EACR-AACR Basic and Translational Research Conference- Tumor Microenvironment. Lisbon, Portugal March 2-4, 2020. DOI: 10.13140/RG.2.2.18422.14400

H. Non-Academic Activity & Positions.

1987-1991 Oncogene Science Inc. Uniondale, New York: Research Scientist, development of cell-based transcription screens

1991-1995 Senior Research Scientist. Cancer Department, group leader of retinoids and angiogenesis drug discovery programs.

1995-1997 Research Investigator. Cancer Department, group leader of apoptosis and tyrosine kisanes drug discovery programs.

2001-2003 Chief Scientific Officer of PlasaMed, Misgav. Israel

2005-2007 Founder and Chief Scientific Officer of MyCure, Meytav Technological Incubator, P.O.B 408, Kiryat Shmona 11013, Israel.

I. Publications

1. MSC thesis:

Hebrew University in Jerusalem: M. Sc. Dept. Molecular Genetics, Amos Oppenheim's Laboratory. Regulation of Lambda Gene Expression

2. Ph.D. thesis:

Hebrew University in Jerusalem: Ph.D. Dept. Molecular Genetics, Amos Oppenheim's Laboratory. Regulation of Lambda Gene Expression.

J. Books :

1. Einat Gochman, Abraham, Z. Reznick and Jamal Mahajna. Involvement of Reactive Nitrogen Species and NF-KB in Colon Cancer. Lab Lambert Academic Publishing (2013), Heinrich-Bocking-Str. 6-8, 66121 Saarbrucken, Deutschland, Germany. (English).

K. Articles in refereed journals

1. Rattray, A., Altuvia, S., Mahajna, J., Oppenheim, A., Gottesman, M. (1984) Control of Bacteriophage Lambda cII activity by Bacteriophage and Host Functions, J. Bacteriol. 159: 238-242

2. Oppenheim, A.B., Mahajna, J., Koby S. and Altuvia, S. (1982) Regulation of the Establishment of Repressor Synthesis in Bacteriophage Lambda, J. Mol. Biol. 155: 121-132

3. Honigman, A., Mahajna, J., Altuvia, S., Koby, S., Teff, D., Locker-Giladi, H., Hyman, H., Kroman, C., and Oppenheim, A.B. (1985) Plasmid Vectors for the Analysis of Transcription Termination signals, Gene 36: 131-141.

4. Mahajna, J., Oppenheim, A.B., Rattray, A., and Gottesman, M. (1986) Translation Initiation of Bacteriophage Lambda Gene cII Requires Integration Host Factor, J. Bacteriol. 165: 167-174

5. Mahajna, J., King, P., Parker, P. and Haley, J. (1995) Autoregulation of Cloned Human Protein Kinase C beta and gamma Gene Promoters in U937 Cells, DNA and Cell Biology 3: 213-222

6. Mahajna, J.*, Shi, B. and Bruskin, A. (1997) A four amino acid insertion in the ligand binding domain inactivates hRXRbeta and renders dominant negative activity. DNA and Cell Biol. 16: 463-476.

7. Shi, B., Triebe, D., Kajiji, S., Iwata, K., Bruskin, A. and Mahajna, J*. (1999). Identification and characterization of Baxepsilon, a Bax variant missing the BH2 and the TM domains. Biochem Biophys Res Commun 254:779-85.

8. Shtayeh S.M., Yaniv Z. and Mahajna, J*. (2000). An ethnobotanical survey in the Palestinian area: A preliminary classification of the healing potential of medicinal plants. J. of Ethnopharmacol. 73: 221-232.

9. Yassin, M., and Mahajna, J*. (2003). Medicinal Mushroom Extracts Selectively Inhibit Proliferation and Induce Differentiation of K562 Human Chronic Myelogenous Leukemia Blast Cells. Int. J. Medicinal Mushroom, 5: 259-274.

10. Konson, A., Abed N. Azab, N., A., Ben-Kasus, T., Mahajna, J., Danon, A., Rimon, G. and Agbaria, R. (2004) Herpes simplex virus thymidine kinase gene transduction enhances tumor growth rate and cyclooxygenase-2 expression in murine colon cancer cells in vitro and in vivo. Cancer Gene Therapy 11: 830-940.

11. Petrova, R. D., Wasser, S.P., Mahajna, J., Denchev, C.V. and Eviatar, E. (2005). Potential Role of Medicinal Mushrooms in Breast Cancer Treatment: Current Knowledge and Future Perspectives. Intern. J. Med. Mush. 7, 135- 149.

12. Petrova, D.R., Wasser, S.P., Mahajna, J., Cvetomir M. Denchev, M.C. & Nevo, E. (2005). Medicinal Mushrooms: A New Source for Breast Cancer Therapeutics. Intern. J. Med. Mush. 7, 445-446.

13. Didukh, Y. M., Wasser, S.P., Nevo, E. & Mahajna, J*. (2005) Screening Antitumor Activity of Low-Molecular-Weight Compounds Obtained from the Fruit Bodies of Family Agaricaceae Chevall. (Higher Basidiomycetes). Intern. J. Med. Mush. 7, 398-400.

14. Mahajna, J*., Yassin, M., Zaidman, B-Z., Nevo, E. and Wasser, S.P. (2005). Medicinal Mushroom Substances As Cancer Molecular Therapy. Intern. J. Med. Mush. 7, 352.

15. Zaidman, B-Z., Yassin, M., Mahajna, J. and Wasser, S.P. (2005). Medicinal Mushroom Modulators of Molecular Targets As Cancer Therapeutics. Journal of Applied Microbiology and Biotechnology. 67: 453-468.

16. Konson, A., Mahajna, J., Danon, A., Rimon, G. and Agbaria, A. (2006). The involvement of nuclear factor Kappa B in cyclooxigenase-2 expression in murine colon cancer cells transduced with herpes simplex virus thymidine kinase gene. Cancer Gene Therapy, 13:1093-1104

17. Zaidman, B.Z., Lutin, A., Wasser, S.P., Nevo, E. and Mahajna, J*. (2007). Adverse effects of mycelia and culture broth extracts from Bjerkandera adusta (Willd.: Fr.) P. Karst. and Hypholoma fasciculare (Huds.: Fr.) P. Kumm. on breast and prostate cancer cells. Intl. J. Med. Mush, 9 (1). 39-46.

18. Zaidman, B., Wasser, P.S., Nevo, E. and Mahajna, J*. (2007). Androgen receptor-dependent and independent mechanisms mediates Ganoderma Lucidium activity on LNCaP prostate cancer cells. Int J Oncol. 31:959-67.

19. Mahajna J*., Zaidman, B., Sussan, S., Dotan, N., Wasser, S.P. and Nevo, E. (2007). Mushroom substances as Therapeutics for hormone-refractory prostate cancer. Intl. J. Med. Mush, 9 (3). 212-213.

20. Petrova, R. D., Ruimi, N., Sussan, S., Wasser, S.P., Nevo, E., Reznick, A.Z., and Mahajna, J*. (2007). Inhibitory Effects of Marasminus oreades extract Fractions on NF-kB Activation Pathway. Intl. J. Med. Mush, 9 (3). 339-340.

21. Zaidman, B., Wasser, P.S., Nevo, A. and Mahajna, J*. (2008). Coprinus comatus and Ganoderma lucidum interfere with Androgen Receptor function in prostate cancer cells. Mol Biol Reports 35: 107-117.

22. Petrova, R.D., Wasser, S.P., Denchev, C.M., Eviatar N., Reznick, A.Z., and Mahajna, J*. (2008). Fungal metabolites modulating NF-kB activity: A new approach to cancer therapy and cancer chemoprevention. Oncology Reports 19: 299-308.

23. Yassin, M., Wasser, S.P. and Mahajna, J*. (2008) Substances from the medicinal mushroom D. Gibbosa inhibit Kinase activity of native and T315I mutated Bcr-Abl. Int. J. Oncol 32: 1197-1204.

24. Mahajna, J.*, Dotan, N., Zaidman, B-Z., Petrova, R.D., and Wasser, S.P. (2009) Pharmacological Values of Medicinal Mushrooms for Prostate Cancer Therapy: The Case of Ganoderma lucidum. Nutrition and Cancer 61: 16-26.

25. Petrova, R.D., Mahajna, J., Wasser, S., P., Ruimi, N., Denchev, C.M., Sherbel S., Eviatar N. & Reznick, A.Z. (2009). Marasmius oreades substances block NF-kB activity in MCF7 breast cancer cells through interference with IKK activation pathway. Mol Biol Rep. 36(4):737-44

26. Ruimi, N., Rwashdeh, H., Wasser, S.P., Konkimalla, B., Efferth, T., Borgatti, M., Gambari, R. and Mahajna, J*. (2010). Daedalea gibbosa substances inhibit LPS-induced expression of iNOS by suppression of NF-kB and MAPK activities in RAW 264.7 macrophage cells. International Journal of Molecular Medicine 25: 421-432.

27. Ruimi, N., Petrova, R.D., Agbaria, R., Sussan, S., Wasser, S.P., Reznick , A.Z. and Mahajna, J*. (2010). Inhibition of TNFa-induced iNOS expression in HSV-tk transduced 9L glioblastoma cell lines by Marasmius oreades substances through NF-kB- and MAPK-dependent mechanisms. Molecular Biology Reports. 37(8):3801-12

28. Dotan, N., Wasser, S.P. & Mahajna, J*. (2011). Crude extracts from the Culinary-medicinal Mushroom Coprinus comatus as Natural Anti-androgenic Modulators. Integrative Cancer Therapies. Integrative Cancer Therapies 10: 148-159.

29. Dotan, N., Wasser, S.P. and Mahajna, J*. (2011) Inhibition of the Androgen Receptor Activity by Coprinus comatus Substances. Nutrition Cancer. 63:1316-27.

30. Khamaisie, H., Sussan, S., Tal , M., Najajreh , Y., Ruthardt, M. and Mahajna, J*. (2011). Oleic acid is the active moiety in the mushroom Daedalea gibbosa that inhibits Bcr-Abl auto-phosphorylation activity. Anticancer Research. 31: 177-183.

31. Mian, A.A., Schüll, M., Oancea, C., Najajreh, Y., Mahajna, J., Goldblum, A., Oliver Gerhard Ottmann, O.G., Beissert, T. and Ruthardt, M. (2011). Targeting the Oligomerization of BCR/ABL by Membrane Permeable Competitive Peptides Inhibits the Proliferation of Philadelphia Chromosome Positive Leukemic Cells. Open Hematology Journal, 5, 21-27

32. Asatiani, D.A, Wasser, S.P., Nevo, E., Ruimi, N., Mahajna, J. and Reznick, A. (2011). Shaggy Inc Cap Medicinal Mushroom, Coprinus comatus (O.F.Mull.:Fr.) Pers. (Agaricomycetideae) Substances Interfere with H2O2 Induction of the NF-kB pathway through inhibition of IkBa phosphorylation in MCF7 Breast Cancer Cells. International Journal of Medicinal Mushrooms, 13 (1): 19-25.

33. Gochman, E., Mahajna, J. & Reznick, A. (2011). A dual mechanism of NF- κB activation by peroxynitrite through p38 MAP kinase dependent IκBα phosphorylation, versus IκBα nitration in colon cancer cells. Anticancer Research 31: 1607-1617.

34. Mian, A.A. , Metodieva, A., Najajreh, Y., Ottmann, O.G., Mahajna, J. and Ruthardt, M. (2012). p185BCR/ABL exhibits a lower sensitivity to the allosteric inhibitor GNF-2 as compared to p210BCR/ABL in Philadelphia chromosome-positive acute lymphatic leukemia. Haematologica. 97:251-7.

35. Gochman, E., Mahajna, J., Shenzera, J., Dahand, A., Blattd, A., Elyakimd, R. and Reznicka, A.Z. (2012). The expression of iNOS and nitrotyrosine in colitis and colon cancer in humans. Acta Histochem. Dec;114(8):827-35.

36. Mian, A.A., Metodieva, A., Badura, S., Khateb, M., Ruimi, N., Najajreh, Y., Ottmann, G.O., Mahajna, J. and Ruthardt, M. (2012). Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I. BMC Cancer. 12:411

37. Khateb, M., Ruimi, N., Khamaisie, H , Najajreh, Y., Mian, A. A., Metodieva, A., Ruthardt, M. and Mahajna, J*. (2012). Overcoming Bcr-Abl T315I mutation by combination of GNF-2 and ATP competitors in an Abl- independent mechanism .BMC Cancer, 12:563.

38. Najajreh, Y., Khamaisie, H., Ruimi, N., Khatib, S., Katzhendler, J., Ruthardt, M., and Mahajna, J*. (2013). Oleylamine-carbonyl-valinol inhibits auto- phosphorylation activity of native and T315I mutated Bcr-Abl, and exhibits selectivity towards oncogenic Bcr-Abl in SupB15 ALL cell lines. Molecular Biology Reports 40(3):2205-13

39. Orgil,O., Schwartz, E., Matityahu,I. , Mahajna, J. and Amir,R. (2014). The antioxidative and anti-proliferative potential of non-edible organs of the pomegranate fruit and tree. LWT - Food Science and Technology 58 (2), 571- 577.

40. Agbarya, A., Ruimi, N., Epelbaum, R., Ben-Arye, E. and Mahajna, J*. (2014). Natural products as potential cancer therapy enhancers: A preclinical update. SAGE Open Medicine: 2, 1-12.

41. Feitelson, M., Arzumanyan, A., Kulathinal, R., Blain, S., Holcombe, R., Mahajna, J., et al., (2015). Sustained Proliferation in Cancer: Mechanisms and Novel Therapeutic Targets. Semin Cancer Biol. 2015 Apr 17. pii: S1044- 579X(15)00014-0. doi: 10.1016/j.semcancer.2015.02.006.

42. Mian A.A., Heberboseh, I., Kidan, N.,Khamaisie, H., Regev, O., Nickola, M., Gal, M., Bloch, E., Ratiei, A., Silani, D., Ottman, O., Biondi, R., Ruthardt, M. and Mahajna J*. (2015). Potential use of allosteric inhibitors as strategy to overcome drug resistance in Ph-positive leukemia. International Journal of Molecular Medicine 36, S26-S26.

43. **Ratzon E, Najajreh Y, Salem R, Khamaisie H, Ruthardt M, Mahajna J*. (2016). Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study. BMC Cancer 16(1):140. doi: 10.1186/s12885-016-2182-8.

44. **Ben-Arye E, Mahajna J, Aly R, Ali-Shtayeh MS, Bentur Y, Lev E, Deng G, Samuels N. (2016). Exploring an herbal "wonder cure" for cancer: a multidisciplinary approach. J Cancer Res Clin Oncol 142(7):1499-508. doi: 10.1007/s00432-016-2175-7.

45. **Orgil, O, Spector L, Holland D, Mahajna J, Amir R. (2016). The anti- proliferative and anti-androgenic activity of different pomegranate accessions. Journal of Functional Foods 26, 517-528

46. **Ben-Arye E, Lavie O, Samuels N, Khamaisie H, Schiff E, Gressel Raz O, Mahajna J*. (2017). Safety of herbal medicine use during chemotherapy in 15

patients with ovarian cancer: a "bedside-to-bench" approach. Medical Oncology, 34(4):54. doi: 10.1007/s12032-017-0910-9.

47. **Kidan N, Khamaisie H, Ruimi N, Roitman S, Eshel E, Dally N, Ruthardt M, Mahajna J*. (2017). Ectopic Expression of Snail and Twist in Ph+ Leukemia Cells Upregulates CD44 Expression and Alters Their Differentiation Potential. J Cancer, 8(19):3952-3968. doi:10.7150/jca.19633.

48. **Patrik Prša, Betül Karademir, Gökhan Biçim, Hatem Mahmoud, Inbal Dahan, A Süha Yalçın, Jamal Mahajna, Irina Milisa (2020). The potential use of natural products to negate hepatic, renal and neuronal toxicity induced by cancer therapeutics. Biochemical pharmacology, 173:113551. doi: 10.1016/j.bcp.2019.06.007

49. **Pavlović, I., Khateb, S., Milisav, I., and Mahajna, J*. (2020). Nutraceuticals for Promoting Longevity. Current Nutraceuticals; Vol 1; 18-32. DOI: 10.2174/2665978601666200213121512

50. **Carmi, Y.K, Mahmoud H., Khamaisi, H., Adawi R.,Gopas, J. and Mahajna, J* (2020). Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion Int. J. Mol. Sci. 21(18), 6533; https://doi.org/10.3390/ijms21186533

51. **Regev, O., Kidan, N., Nicola, M., Hazem Khamisie, H., Ruthardt M and Mahajna, J.* (2020). Mesenchymal soluble factors confer imatinib drug resistance in chronic myelogenous leukemia cells. Archive in Medical sciences. DOI: https://doi.org/10.5114/aoms.2020.101042, IF 2.8 Q1 (Medicine)

52. **Mian, AA, Haberbosch, I., Khamaisie, H., Agbarya, A., Pietsch, L., Eshel, E., Dally, N., Claudia Chiriches, C., Ottmann, O., Hantschel, O., Biondi, R., Ruthardt, M., and Mahajna, J*. (2020) Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR/ABL1 and its resistance and compound mutants BCR/ABL1T315I and BCR/ABL1T315I-E255K. Accepted for publication in Annals of Hematology. IF 2.9 Q1 (Medicine), Q2 (Hematology)

Articles or chapters in refereed books 1. Oppenheim, A.B., Mahajna, J., Altuvia, S., Koby, S., Teff, D., Locker- Giladi, H., Hyman, H., and Honigman, A. (1985) Utilization of Lambda Control Elements for Gene Expression Studies in E. Coli, In recombinant DNA Research and Viruses, Becker, Y., ed., Martinus Nijhoff Publishing, Boston, p. 73.

2. Ruimi, N., Dotan, N., Menachem, N., Bartuv-Tal, J. and Mahajna, J. (2010). Mushroom-derived substances for cancer prevention and treatment. In Bioactive foods and extracts in Cancer Treatment and Prevention. R.R Watson and V.R. Preedy ed, Tylor and Francis Group publishing, Boca Raton, Florida, USA Pages 223-236

3. Gochman, E., Reznick, AZ., and Mahajna, J. (2013). Involvement of Reactive Nitrogen Species and NF-B in Colon Cancer. Lab Lambert Academic Publishing, Heinrich-Bocking-Str. 6-8, 66121 Saarbrucken, Deutschland, Germany. (English).

Other publications (in Hebrew) 1. Hila Tobi-Schwartzman, Yehudit Bartov-Tal, Nesli Dotan, Prof. Wasser Solomon and Dr. Jamal Mahajna, "Mushrooms as a Source of Anti-Cancer Substances", published July 31, 2007 in "The Medical"

Miscellaneous Patents:

1. Mahajna, J., Yassin, M, Wasser, S. (2007). Mushroom extracts having anticancer activity. US Patent 7258862

Membership in editorial boards of journals

1. Regional editor in “Current Nutraceuticals” 2. Editor in “Evidence-Based Complementary and alternative medicine” 3. Editor in “International Scholarly Research Notices (molecular biology)”, a peer-reviewed, open access journal.

4. Reviewer in the journals of

o Journal of Cancer o International Journal of Cancer (IJC) o Archive Biochemistry and Biophysics (ABB) o Onco-Targets o Drug Design development and therapy o BMC complementary and alternative therapy o BMC Cancer o Genes and Nutrition

5. Reviewers of Scientific proposal refereed by the Israeli Ministry of Science 6. Reviewers of Scientific proposal refereed by the National Science Centre of Poland